Currently, FSH treatment is mainly administrated to two types of patients: patients with hypogonadotropic hypogonadism (HH) and normogonadotropic patients with idiopathic impairment of spermatogenesis [187]. Here, BRD2 is linked to hypogonadotropic hypogonadism.